Long term safety and survival with gefitinib in select patients with advanced non small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)
This is the first report of long term >10 years) safety, tolerability, and survival data on patients with non small cell lung cancer (NSCLC) who received treatment with gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Cancer